Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Deferred Revenue: 2017-2023

Historic Current Deferred Revenue for Denali Therapeutics (DNLI) over the last 4 years, with Jun 2023 value amounting to $1.3 million.

  • Denali Therapeutics' Current Deferred Revenue was N/A to $1.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $290.1 million for FY2022, which is 939.06% up from last year.
  • Latest data reveals that Denali Therapeutics reported Current Deferred Revenue of $1.3 million as of Q2 2023, which was down 99.55% from $290.4 million recorded in Q1 2023.
  • Over the past 5 years, Denali Therapeutics' Current Deferred Revenue peaked at $290.4 million during Q1 2023, and registered a low of $23,000 during Q3 2022.
  • Over the past 3 years, Denali Therapeutics' median Current Deferred Revenue value was $9.3 million (recorded in 2021), while the average stood at $78.7 million.
  • Over the last 5 years, Denali Therapeutics' Current Deferred Revenue had its largest YoY gain of 939.06% in 2022, and its largest YoY loss of 98.26% in 2022.
  • Over the past 5 years, Denali Therapeutics' Current Deferred Revenue (Quarterly) stood at $18.7 million in 2019, then grew by 6.27% to $19.9 million in 2020, then surged by 40.18% to $27.9 million in 2021, then skyrocketed by 939.06% to $290.1 million in 2022, then reached $1.3 million in 2023.
  • Its last three reported values are $1.3 million in Q2 2023, $290.4 million for Q1 2023, and $290.1 million during Q4 2022.